- Published at
- by manilatimes.net
mixed
mixed
News for Hard to Treat Diseases Inc. (HTDS)
- Published at
- by investing.com
positivepositiveEarnings call: Sobi reports robust Q3 growth, upgrades 2024 guidance By Investing.com
Earnings call: Sobi reports robust Q3 growth, upgrades 2024 guidance- Published at
- by investing.com
mixedmixedOtsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults By Investing.com
Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults- Published at
- by marketscreener.com
mixedmixedPharmaCyte Biotech : Releases Statement on Nasdaq Uplisting and Current Business Focus
PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today... | August 16, 2021- Published at
- by news.google.com
mixedmixedPharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
LAGUNA HILLS, Calif., August 16, 2021--PharmaCyte releases statement on Nasdaq uplisting and current business focus.- Published at
- by thestreet.com
mixedmixedPharmaCyte Biotech Releases Statement On Nasdaq Uplisting And Current Business Focus
PharmaCyte Biotech, Inc. PMCB (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its